[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hepatoid-adenocarcinoma-of-stomach\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hepatoid-adenocarcinoma-of-stomach":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100592356","phase-2-perioperative-treatment-of-hepatoid-adenocarcinoma-of-stomach-100592356",false,"NCT06992362","Perioperative Treatment of Hepatoid Adenocarcinoma of Stomach","Prospective, Single-arm, Single-center Phase II Clinical Study of Perioperative Precision Treatment for Locally Advanced Hepatoid Adenocarcinoma of Stomach","HASCHANGE01","Inclusion Criteria:\n\n* The histological type of gastric hepatoid adenocarcinoma was confirmed by pathological biopsy；\n* HER2 expression (Immunohistochemistry: 1+,2+,3+);\n* Patients with clinical stage II-III;\n* Those who are expected to complete R0 excision;\n* ECOG score 0\\~1;\n* Generally in good condition, perioperative treatment and surgical resection can be tolerated;\n* Patients were enrolled voluntarily.\n\nExclusion Criteria:\n\n* Combined with other malignant tumors (excluding thyroid papillary carcinoma, facial basal cell carcinoma and other low-grade malignant tumors); -Patients with obstruction, bleeding, etc. who need surgical intervention after evaluation by clinicians;\n* dMMR\u002FMSIH status；\n* Received other anti-tumor therapy before enrollment.","ALL","18 Years","75 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The goal of this clinical trial is to learn if treatment modality including Disitamab Vedotin （RC48）, Oxaliplatin，Tegafur,Gimeracil and Oteracil Porassium Capsules （SOX）and Sindillimab works to treat locally advanced hepatoid adenocarcinoma of stomach. It will also learn about the safety of this modality. The main aim it aims to achieve are:\n\n* To evaluate the perioperative efficacy of RC48 combined with sindillizumab and SOX in the treatment of locally advanced HER2-expressing hepatoid adenocarcinoma of stomach\n* To evaluate the safety and long-term benefits of RC48 combined with sindillizumab and SOX regimens in perioperative treatment of locally advanced HER2-expressing hepatoid adenocarcinoma of stomach\n\nParticipants will:\n\n* Preoperative treatment with RC48, SOX and sindillizumab for 4 cycles\n* Radical surgery after 4-6 weeks of the preoperative treatment\n* Adjuvant treatment with RC48, Tegafur,Gimeracil and Oteracil Porassium Capsules and sindillizumab for 4 cycles",[28],"Hepatoid Adenocarcinoma of Stomach",[30,31,32,33,34],"HER2","SOX","PD-1 inhibitor","Disitamab Vedotin","perioperative treatment","RECRUITING","2026-09-19",{"date":38,"type":39},"2026-09-22","ACTUAL",{"date":41,"type":39},"2025-05-20",{"date":43,"type":22},"2029-12-31",{"name":45,"class":46},"Peking University Cancer Hospital & Institute","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":47},"100606652","phase-2-perioperative-therapy-for-her2-negative-hepatoid-adenocarcinoma-of-stomach-100606652","NCT07178340","Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach","Prospective, Single-arm, Single-center Phase II Clinical Study of Perioperative Therapy for Locally Advanced HER2-negative Hepatoid Adenocarcinoma of Stomach","HASCHANGE02","Inclusion Criteria:\n\n* The histological type of gastric hepatoid adenocarcinoma was confirmed by pathological biopsy；\n* HER2 negative (Immunohistochemistry: 0);\n* Patients with clinical stage II-III;\n* Those who are expected to complete R0 excision;\n* ECOG score 0\\~1;\n* Generally in good condition, perioperative treatment and surgical resection can be tolerated;\n* Patients were enrolled voluntarily.\n\nExclusion Criteria:\n\n* Combined with other malignant tumors (excluding thyroid papillary carcinoma, facial basal cell carcinoma and other low-grade malignant tumors); -Patients with obstruction, bleeding, etc. who need surgical intervention after evaluation by clinicians;\n* dMMR\u002FMSIH status；\n* Received other anti-tumor therapy before enrollment.",{"count":21,"type":22},[25],"The goal of this clinical trial is to learn if treatment modality including albumin-bound paclitaxel, oxaliplatin, tegafur,gimeracil and oteracil porassium capsules (SOX) and sintilimab works to treat locally advanced HER2-negative hepatoid adenocarcinoma of stomach. It will also learn about the safety of this modality. The main aim it aims to achieve are:\n\n* To evaluate the perioperative efficacy of albumin-bound paclitaxel combined with sintilimab and SOX in the treatment of locally advanced HER2-negative hepatoid adenocarcinoma of stomach\n* To evaluate the safety and long-term benefits of albumin-bound paclitaxel combined with sintilimab and SOX regimens in perioperative treatment of locally advanced HER2-negative hepatoid adenocarcinoma of stomach\n\nParticipants will:\n\n* Preoperative treatment with abumin-bound paclitaxel, SOX and sintilimab for 4 cycles\n* Radical surgery after 4-6 weeks of the preoperative treatment\n* Adjuvant treatment with albumin-bound paclitaxel, tegafur,gimeracil and oteracil porassium capsules and sintilimab for 4 cycles",[28],[30,31,32,34],"2025-11-24",{"date":63,"type":39},"2025-12-02",{"date":65,"type":39},"2025-09-18",{"date":67,"type":22},"2028-09-20",{"name":45,"class":46}]